Nb‐UVB and PUVA therapy in treating early stages of Mycosis Fungoides: A single‐center cross‐sectional study

Abstract

AbstractIntroductionMycosis fungoides (MF) and Sezary Syndrome are the most common forms of cutaneous T‐cell lymphoma. Early‐stage MF is known to have an indolent behavior, and the EORTC guidelines recommend treating patients with skin‐directed therapies, such as phototherapy, instead of systemic therapies. Phototherapy is a popular therapeutic option, with two commonly used light sources—PUVA and narrow band‐nb UVB. PUVA is less commonly used due to its potential carcinogenic role, but it has systemic effects, while nb‐UVB has mostly skin‐limited effects. There is ongoing debate regarding the role of UVB light, and in 2021, the Cutaneous Lymphoma Italian Study Group reached a consensus on technical schedules for NB‐UVB and PUVA for MF. This study aims to analyze and compare the efficacy of the two phototherapy options in treating early‐MF patients.Materials and methodsThe study included patients diagnosed with stage IA/B MF in the last 10 years, who had at least 12 months of follow‐up data and a minimum of 24 phototherapy sessions (PUVA or nb UVB) and treated with topical steroids apart from phototherapy.ResultsResults showed that the two phototherapy options were similarly effective in treating early MF, with no significant differences in clinical response, although PUVA was associated with more adverse effects.ConclusionsThe study provides valuable insights into the use of phototherapy in early MF, and the results can be used to guide treatment decisions and improve patient outcomes.